Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00591383 | Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors | completed | Phase 1 | 10 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00591422 | Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas | completed | Phase 1 | 23 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00592163 |
| Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas |
| completed |
| Phase 1 |
| 20 |
| Alaunos TherapeuticsINDUSTRY |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT00607711 | Study of Oral Palifosfamide Tris in Solid Tumors | withdrawn | Phase 1 | 0 | Alaunos TherapeuticsINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT00726687 | Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01340547 | Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01770418 | A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 32 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02498912 | Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | active not recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03187288 | Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | completed | Phase 1 | 13 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03679650 | Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients | active not recruiting | Phase 1 | 28 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03707808 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab(myDAvIpNi) | active not recruiting | Phase 1 / Phase 2 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03802695 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | recruiting | Phase 1 | 300 | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03837899 | Durvalumab and Tremelimumab for Pediatric Malignancies | active not recruiting | Phase 1 / Phase 2 | 50 | AstraZenecaINDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT03842228 | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations(COD) | active not recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 10 | Abivax S.A.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04072952 | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer(mBC) | completed | Phase 1 / Phase 2 | 219 | Arvinas Estrogen Receptor, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04085887 | Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures | recruiting | Phase 1 / Phase 2 | 12 | Stanford UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04111458 | A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | active not recruiting | Phase 1 | 71 | Boehringer IngelheimINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | active not recruiting | Phase 1 | 56 | University of WashingtonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04396821 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 150 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04401020 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | terminated | Phase 1 | 47 | SanofiINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT04495296 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04605913 | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | active not recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04717375 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 125 | SanofiINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT04958239 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | active not recruiting | Phase 1 | 151 | Boehringer IngelheimINDUSTRY | 15 | Sep 29, 2026 | clinicaltrials |
| NCT05079282 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | active not recruiting | Phase 1 | 217 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05273554 | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05304208 | dENdritic Cell Therapy Combined With SURgEry in Mesothelioma(ENSURE) | recruiting | Phase 1 | 16 | Erasmus Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma(ASIST) | active not recruiting | Phase 1 / Phase 2 | 195 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05611034 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | recruiting | Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | suspended | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05741242 | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 136 | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05803382 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05845671 | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | active not recruiting | Phase 1 / Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05875168 | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 590 | Daiichi SankyoINDUSTRY | 8 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy(DURIPANC) | active not recruiting | Phase 1 / Phase 2 | 43 | Joachim Aerts, MD PhDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT06098651 | A Study of DCR-STAT3 in Adults With Solid Tumors | completed | Phase 1 | 26 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06487481 | Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06667687 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | suspended | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials